Cough Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop Previous ACE-i Treatment Due to Cough
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 980
- 主要终点
- Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough
研究概览
简要总结
In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hypertension
- •Age > 18
- •ACE-I related cough
排除标准
- •Current treatment with telmisartan
- •Cholestatic disorders and severe hepatic failure
- •Allergy to telmisartan
- •Pregnancy and lactation period
研究组 & 干预措施
Group 1
干预措施: Telmisartan (Kinzal/Pritor, BAY68-9291) (Drug)
结局指标
主要结局
Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough
时间窗: 4 months after initiation
次要结局
- Number of Participants with Adverse Events among patients, who had to stop their previous ACE-I treatment due to cough(4 months after initiation)